10 of John Buckingham’s Favorite Overlooked Stocks
We think that demographics and health care are favorable over the long haul. So health care is a growth area we like to invest in. Johnson & Johnson (JNJ): In the businesses of pharma and medical devices, the diversified company has a super-high-quality triple-A credit rating, a 3% dividend yield and a terrific balance sheet. It’s taken a meaningful step toward final resolution of the multi-year litigation — which will cost $13.7 billion payable over 25 years — concerning the pending talc lawsuits against the company and its affiliates in the U.S. The MedTech segment is expected to grow revenue north of 6% in each of the next few years. We think the litigation will eventually play out, and that certainly could be a catalyst for the stock to come back. The multi-year consolidation in shares offers a great entry point for investors to pick up a defensive, long-term growth opportunity at a reasonable P-E. Molson Coors (TAP): An amalgamation of three brewing companies, Molson, Coors and Miller, the company offers brands across the value spectrum. The stock is inexpensive, trading for less than 10 times earnings per share projected in each of the next few years, though management is faced with...